Silence Therapeutics plc (LON:SLN – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 535 ($6.72) and traded as low as GBX 512 ($6.43). Silence Therapeutics shares last traded at GBX 535 ($6.72), with a volume of 913,528 shares trading hands.
Silence Therapeutics Price Performance
The business’s fifty day moving average price is GBX 535 and its 200-day moving average price is GBX 535. The company has a market capitalization of £480.35 million and a P/E ratio of -11.01. The company has a current ratio of 4.52, a quick ratio of 4.36 and a debt-to-equity ratio of 0.80.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Featured Articles
- Five stocks we like better than Silence Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- Garmin Navigates to New Highs Driven By Wearables Trend
- Market Cap Calculator: How to Calculate Market Cap
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- 3 Fintech Stocks With Good 2021 Prospects
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.